BioCentury
ARTICLE | Company News

SHR acquires ABT dermatitis compound

November 6, 2001 8:00 AM UTC

Schering (SHR) acquired the worldwide rights to develop and market ABT-281, a topical non-steroidal immunosuppressant from Abbott (ABT), for atopic dermatitis and other dermatological diseases. ...